---
title: "KYMR.US (KYMR.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/KYMR.US/news.md"
symbol: "KYMR.US"
name: "KYMR.US"
parent: "https://longbridge.com/zh-HK/quote/KYMR.US.md"
datetime: "2026-03-13T13:21:37.691Z"
locales:
  - [en](https://longbridge.com/en/quote/KYMR.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KYMR.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KYMR.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/KYMR.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/KYMR.US/news.md)


# KYMR.US (KYMR.US) — 相關新聞

### [How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors](https://longbridge.com/zh-HK/news/277640072.md)
*2026-03-03T14:38:06.000Z*
> Kymera Therapeutics reported a net loss of $311.35 million for 2025 and announced a $500 million at-the-market equity pr

### [TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR](https://longbridge.com/zh-HK/news/277466739.md)
*2026-03-02T12:53:09.000Z*
> TD Asset Management Inc reduced its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 10.9% in Q3, now owning 209,2

### [Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029](https://longbridge.com/zh-HK/news/277321086.md)
*2026-02-28T18:32:15.000Z*
> Kymera Therapeutics is shifting its focus to immunology and inflammation, as highlighted at Oppenheimer’s 36th Annual He

### [Juheng News - Factset's latest survey: Kymera Therapeutics Inc (KYMR-US) EPS estimate revised down to -3.76 yuan, estimated target price is 118.00 yuan](https://longbridge.com/zh-HK/news/277091481.md)
*2026-02-26T20:15:37.000Z*
> According to the latest survey by FactSet, the median EPS estimate for Kymera Therapeutics Inc (KYMR-US) for 2026 has be

### [Analyst Expectations For Kymera Therapeutics's Future](https://longbridge.com/zh-HK/news/277092422.md)
*2026-02-26T20:01:16.000Z*
> 22 analysts have provided varied opinions on Kymera Therapeutics (NASDAQ:KYMR), with recent ratings showing a mix of bul

### [BTIG Research Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $134.00](https://longbridge.com/zh-HK/news/277087175.md)
*2026-02-26T19:22:59.000Z*
> BTIG Research has lowered its price target for Kymera Therapeutics (NASDAQ:KYMR) from $138.00 to $134.00 while maintaini

### [Sector Update: Health Care Stocks Edge Higher Pre-Bell Thursday](https://longbridge.com/zh-HK/news/277059391.md)
*2026-02-26T14:11:00.000Z*
> Health care stocks showed a slight increase pre-bell on Thursday, with the State Street Health Care Select Sector SPDR E

### [Kymera Therapeutics | 10-K: FY2025 Revenue Misses Estimate at USD 39.21 M](https://longbridge.com/zh-HK/news/277038844.md)
*2026-02-26T12:18:45.000Z*